Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook
November 15, 2016 7:01 AM EST(Updated - November 15, 2016 7:05 AM EST)
Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $5.56 billion versus the consensus estimate of $5.75 billion.
The company sees Q3 EPS of $1.34 - $1.44 with... More
